New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 8, 2014
09:03 EDTSGEN, TKPYYSeattle Genetics to receive milestone payments from Takeda on Adcetris
Seattle Genetics (SGEN) announced that it will receive milestone payments from Takeda (TKPYY) totaling $6M as a result of achieving the first commercial sale of ADCETRIS in three key countries in Takeda’s territories outside of the European Union and Japan, consisting of Australia, South Korea and Mexico. All three countries have permission to sell commercial product from their local health authority for the treatment of patients with relapsed or refractory CD30-positive Hodgkin lymphoma and systemic anaplastic large cell lymphoma. In addition to these three countries, ADCETRIS is also commercially available in the U.S., European Union, Japan, Canada, Ukraine, Switzerland, Singapore, Norway, Liechtenstein and Iceland. ADCETRIS is an antibody-drug conjugate directed to CD30, a defining marker of classical HL and known to be expressed in some types of non-Hodgkin lymphoma, including sALCL.
News For SGEN;TKPYY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 15, 2015
08:33 EDTTKPYYFDA panel results positive for Merck, says SunTrust
Subscribe for More Information
April 14, 2015
07:15 EDTTKPYYFDA Endocrinologic & Metabolic Drugs Advisory Committee holds a meeting
Subscribe for More Information
April 13, 2015
08:54 EDTTKPYYAstraZeneca has negative read through from briefing docs, says SunTrust
Subscribe for More Information
April 10, 2015
07:21 EDTSGENExpert upbeat on Seattle Genetics Adcetris, says RBC Capital
After meeting with an expert, RBC Capital reports that he believes that off-label use of Seattle Genetics' Adcetris is increasing across a variety of indications. He believes that Adcetris is approvable and has a better chance of becoming a front-line treatment than competing drugs. The firm keeps a $50 price target and Outperform rating on the shares.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use